INVIVYD, INC. Realized Investment Gains (Losses)
INVIVYD, INC. (IVVD) reported Realized Investment Gains (Losses) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2025-03-20
- INVIVYD, INC. realized investment gains (losses) for fiscal 2024 was $0.00.
- INVIVYD, INC. realized investment gains (losses) for fiscal 2023 was $0.00.
| Period end | Realized Investment Gains (Losses) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |